day 3 uterine transfer for Infertility
This study is evaluating whether the day of embryo transfer impacts the success of in vitro fertilization.
See full descriptionAbout the trial for Infertility
Treatment Groups
This trial involves 2 different treatments. Day 3 Uterine Transfer is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Eligibility
This trial is for female patients between 18 and 65 years old. There are 2 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether day 3 uterine transfer will improve 1 primary outcome and 4 secondary outcomes in patients with Infertility. Measurement will happen over the course of 14 days.
Who is running the study
Principal InvestigatorPatient Q & A Section
Can infertility be cured?
Treatable conditions of infertility could be considered a cure, provided that all factors are evaluated by a physician within the context of the patient's personal life and wishes.
What is infertility?
Infertility, also known as inability to conceive a child, is the inability to bear and then deliver a pregnancy of sufficient numbers of healthy live-born children per woman after a period of time. In 2015, there were 311 million couples around the world who need assistance to conceive. More than 80% of couples will be successful in achieving pregnancy within 3 to 5 years. While most couples have some options to treat their infertility, not all options offer the same chance of successful treatment outcomes. What are the most important factors in choosing treatment options? answer: Knowledge of these key factors should assist healthcare practitioners towards selecting the best treatment option for their patients.
What causes infertility?
A number of possible causes of infertility were found, including tubal diseases and endometrial disorders for women with infertility, male infertility and factor I dysfunction.
What are the signs of infertility?
Some of the signs of infertility involve the absence of menstruation and/or persistent vaginal discharge, such as an irritant fluid on the speculum. In contrast, other signs could be the presence of blood and white, yellow or green in the discharge, or a heaviness in the abdomen on examination. Most importantly, it is the presence of pain while sexual intercourse is very important, in spite of what the symptoms might be.
How many people get infertility a year in the United States?
About 400,000 women in the United States have an unfavourable male factor subfertility at one time or another each year. There is some evidence that women with recurrent infertility are more likely to have an autoimmune disease.
What are common treatments for infertility?
Infertility is commonly treated with hormonal analogs such as clomiphene or gonadotropins such as FSH. Anti-inflammatory therapy may also be tried. Other treatments include assisted reproductive technology (ART), which refers to the use of technology to assist in the reproductive process, including procedures such as in vitro fertilization (IVF), and the transplantation of gametes into another person.\n
What are the latest developments in day 3 uterine transfer for therapeutic use?
A new technique called Day 3 Uterine Transfer is effective in aiding women to conceive in the long term. This method is relatively simple, easy to perform and very affordable. It is one of the most successful techniques to treat infertility and it can be used as a first step of IUI therapy in those cases where the embryo is at advanced stage of developmental. Further studies are needed to evaluate all the possible ways and the best timing for this kind of therapeutic procedure
Is day 3 uterine transfer typically used in combination with any other treatments?
Pregnancy and live birth rates were acceptable in this case series. In the case series of azoospermic men, transfer on the third day after orvietectomy provided live birth in almost half of cases; even more so for men with an idiopathic azoospermia.
What is the latest research for infertility?
The development of fertility drugs is still in the early stages of research. There are many factors that are necessary to take into consideration before choosing to treatment options. In terms of drugs, they are used to treat a number of conditions. However, because of the wide range of symptoms affecting women, there are many different treatment options. The main objective of these agents is to treat the symptoms of female infertility. This includes the reasons why women have such conditions, the age group at which the woman is diagnosed with infertility, and the duration of infertility. For example, if the patient's primary issues revolve around menstruation issues, then the treatment option is to use drugs to treat these.
Has day 3 uterine transfer proven to be more effective than a placebo?
Day 3 embryo transfer seems to be at least equally as effective as AET. Day 3 embryo transfer, in contrast to day 6 embryo transfer, should be recommended to all women with an endometrial thickness of 8 to 12 mm as well as to all women with an endometrial layer on the uterine sidewalls of 10 to 12 mm.
Who should consider clinical trials for infertility?
On reviewing the data from the clinical trials evaluating infertility treatments it is impossible to state with certainty which treatments are most useful for which infertility problems. The decision whether to take up a treatment for infertility or not also depends on multiple other factors, including cost and the availability of treatment, as well as the willingness to put up the financial and time to receive a treatment. In clinical trials there is always a tendency for the results to be interpreted as more favourable than what might otherwise be the case. The best way to avoid this is to include as few people as possible who have a surrogate mother when performing studies evaluating fertility treatments, thus avoiding maternal bias of the patients when interpreting the data.